ProCE Banner Activity

Best Practices in Testing and Treatment for Advanced ALK-Positive NSCLC and Overcoming Challenges to Implementation in Clinical Practice

Clinical Thought

In this focused commentary, experts discuss contemporary testing and treatment for advanced ALK-positive NSCLC and reflect on real-world clinical needs in these areas.

Released: April 21, 2025

Expiration: October 20, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Disclosure

Primary Author

Todd M. Bauer, MD: consultant/advisor/speaker: Bayer, FMI, Pfizer, Tempus.

Jessica J. Lin, MD: consultant/advisor/speaker: AnHeart Therapeutics, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, C4 Therapeutics, Claim Therapeutics, Daiichi Sankyo, Elevation Oncology, Ellipses, Genentech, Gilead, Janssen, Lilly, Merus, Mirtati Therapeutics, Novartis, Nuvation Bio, Nuvalent, Pfizer, Regeneron, Roche, Takeda, Turing Point Therapeutics, Yuhan; researcher (paid to institution): Bayer, Elevation Oncology, Hengrui Therapeutics, Linnaeus Therapeutics, Neon Therapeutics, Novartis, Nuvalent, Roche, Relay Therapeutics, Turning Point Therapeutics; other (travel support): Bristol Myers Squibb, Merus, Pfizer, Takeda.

Alexander Craig Mackinnon, Jr., MD, PhD, MSHA, has no relevant financial relationships to disclose.

Beth Sandy, MSN, CRNP, FAPO: consultant/advisor/speaker: Amgen, AstraZeneca, Jazz, Lilly, Merck, Pfizer, Takeda.